Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs MedLeanRx
Two GLP-1 providers, compared side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
Published by The GLP-1 Verdict
Pricing sources checked: CoreAge Rx: August 2026 · MedLeanRx: Check date not recorded
vs
Verdict69/ 100
Grade C · #196MedLeanRx
MedLeanRx is a physician-guided telehealth weight-loss clinic serving Texas only, based in Spring, TX.
Visit MedLeanRxThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 69/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. MedLeanRx still earns its place — shoppers who want texas-only compounded semaglutide at $149/mo with a brand Wegovy and Zepbound pathway.
The score compares published program terms and features; it does not measure clinical outcomes or predict which treatment will suit you.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results80
92
Real-world results80
97Price honesty64
97
Price honesty64
96Prescriber access51
96
Prescriber access51
88Formulary choice92
88
Formulary choice92
95Cancellation fairness56
95
Cancellation fairness56
93Member support70
93
Member support70
Price, coverage & features
| Metric | CoreAge Rx | MedLeanRx |
|---|---|---|
| Verdict Score | 94/100 | 69/100 |
| Grade | A | C |
| Semaglutide | $99/mo | From $149/mo (starting dose, promotional rate, compounded) |
| Tirzepatide | $149/mo | From $269/mo (starting dose, compounded) |
| Coverage | All 50 states | 1 state |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | No | Yes |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
MedLeanRx
What we like
- Compounded semaglutide $149/mo in both weekly injection and daily oral tablet form
- Brand pathway for Wegovy, Zepbound, and Foundayo (orforglipron) at a $99/mo fee plus medication cost
- Intro bundle: 2 months of compounded tirzepatide (2 mg weekly) for $325 — about $163/mo
- LegitScript seal displayed; named supervising physician (Dr. Johnson Uzor, MD)
- Free shipping, no hidden fees, and cancel-anytime plans per homepage trust chips
The caveats
- Texas only — not available in the other 49 states
- Compounded tirzepatide is $269/mo at standard pricing, above the ~$249 market median
- Strict no-refund policy: 'All sales are final' per Terms & Conditions
- Pharmacy partner not publicly named — a transparency gap for a compounding service
- Legal entity name and founding details not published on the site
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Shoppers who want texas-only compounded semaglutide at $149/mo with a brand Wegovy and Zepbound pathway.
Visit MedLeanRx Read the full MedLeanRx review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for MedLeanRx does the reverse.
More on CoreAge Rx
More on MedLeanRx
Or browse the full comparison hub, every head-to-head A to Z and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.